Search Results

You are looking at 1 - 10 of 26 items for :

  • Refine by Access: All x
Clear All
Full access

Daniel Y. C. Heng and Toni K. Choueiri

] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract 5025 37 Eder JP Heath E Appleman L . Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1

Full access

Patrick C. Ma and Ravi Salgia

: 6304 – 6311 . 30 Ma PC Kijima T Maulik G . c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions . Cancer Res 2003 ; 63 : 6272 – 6281 . 31 Krystal GW

Full access

Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih

validated. 19 - 21 Other molecular characteristics have been implicated in the prognosis and response of colorectal cancer to various therapeutics agents. C-met overexpression has been associated with resistance to cetuximab treatment in primary xenograft

Full access

Chloe E. Atreya, Eric A. Collisson, Meyeon Park, James P. Grenert, Spencer C. Behr, Amalia Gonzalez, Jonathan Chou, Samantha Maisel, Terence W. Friedlander, Chris E. Freise, Jun Shoji, Thomas J. Semrad, Jessica Van Ziffle, and Peter Chin-Hong

/PR normal specimen. (B) Copy number changes identified by NGS in tumors from the LR and the K/PR. (C) MET amplification on the left kidney recipients’ tumor specimen, detected by fluorescence in situ hybridization. A probe at 7q11.1 (green) and a MET

Full access

the signaling pathways of VEGF/VEGFR, EGF/EGFR, PDGF/PDGFR-β, IL-6, IL-8, HGF/c-met, FGF/FGFR, Jak2, and STAT3, and their effects on microvessel density in the tumors. Therefore, it is postulated that assessing the levels and activity of these

Full access

antitumor effect through influencing the signaling pathways of VEGF/VEGFR, EGF/EGFR, PDGF/PDGFR-beta, IL-6, IL-8, HGF/c-met, FGF/FGFR, Jak2, STAT3, and effect on microvessel density in the tumors. Therefore, the investigators postulate that assessing the

Full access

Tayyaba Hasan

response to photodynamic therapy (PDT) may be a key to developing mechanism-based combination treatments with PDT. In addition, Dr. Hasan’s group also examined c-MET activity in this same pancreatic cancer animal model. Sublethal PDT stimulated c-MET

Full access

Toni K. Choueiri and Robert J. Motzer

) [abstract] . J Clin Oncol 2015 ; 33 ( Suppl ): Abstract 4506 . 7. Sennino B Ishiguro-Oonuma T Wei Y . Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

Full access

Brian Vicuna and Al B. Benson III

. Sinicrope FA Rego RL Halling KC . Thymidylate synthase expression in colon carcinomas with microsatellite instability . Clin Cancer Res 2006 ; 12 : 2738 – 2744 . 28. Resnick MB Routhier J Konkin T . Epidermal growth factor receptor, c-MET

Full access

Dwight H. Owen, Bhavana Konda, Jennifer Sipos, Tom Liu, Amy Webb, Matthew D. Ringel, Cynthia D. Timmers, and Manisha H. Shah

on primary resistance and included alternate BRAF splicing, 23 c-MET–mediated reactivation of the PI3K/AKT pathway, 24 and copy number gain of MCL1 and loss of CDKN2A. 25 Potential resistance mechanisms to BRAF and/or MEK inhibition, described in